AE leading to discontinuation in the population reaching T2 (n=1432)
| Adverse events | N (%) |
|---|---|
| Cognitive disturbances | 9 (0.6) |
| Psychiatric symptoms | 46 (3.2) |
| Fatigue | 36 (2.5) |
| Drowsiness | 32 (2.2) |
| Dizziness | 30 (2.0) |
| Gastrointestinal symptoms | 21 (1.4) |
| Mouth discomfort | 10 (0.7) |
| Allergic reaction | 3 (0.2) |
| Other neurological symptoms | 16 (1.1) |
| Not available | 100 (7) |
| SAE | 5 (0.3) |
AE, adverse event; SAE, serious adverse event.